Hiroshi Ueoka
Overview
Explore the profile of Hiroshi Ueoka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sato K, Takigawa N, Kubo T, Katayama H, Kishino D, Okada T, et al.
Acta Med Okayama
. 2023 Feb;
77(1):65-70.
PMID: 36849147
We investigated the effects of celecoxib combined with (-)-epigallocatechin-3-gallate (EGCG) or polyphenon E in a cisplatin-induced lung tumorigenesis model. Four-week-old female A/J mice were divided into seven groups: (i) Control,...
2.
Oishi K, Aoe K, Mimura Y, Murata Y, Sakamoto K, Koutoku W, et al.
Intern Med
. 2016 Dec;
55(24):3551-3559.
PMID: 27980253
Objective Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are fatal episodes of acute respiratory worsening of unknown etiology. Previous studies on acute respiratory distress syndrome have shown that direct hemoperfusion...
3.
Kubo T, Fujiwara K, Hotta K, Okada T, Kuyama S, Harita S, et al.
Cancer Chemother Pharmacol
. 2016 Aug;
78(4):769-74.
PMID: 27544764
Purpose: The treatment outcome in elderly patients with limited-disease small-cell lung cancer (LD-SCLC) remains poor. We carried out a phase II trial of split topotecan and cisplatin (TP) therapy and...
4.
Mimura Y, Kelly R, Unwin L, Albrecht S, Jefferis R, Goodall M, et al.
J Immunol Methods
. 2015 Dec;
428:30-6.
PMID: 26627984
Glycosylation of the IgG-Fc is essential for optimal binding and activation of Fcγ receptors and the C1q component of complement. However, it has been reported that the effector functions are...
5.
Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, et al.
J Thorac Oncol
. 2015 Feb;
10(3):486-91.
PMID: 25695221
Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. We conducted a phase II...
6.
Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, et al.
Lung Cancer
. 2014 Dec;
87(2):141-7.
PMID: 25534129
Background: Although cisplatin-based chemotherapy combined with thoracic irradiation (TRT) is a standard treatment for unresectable, locally advanced non-small cell lung cancer (NSCLC), this treatment outcome has remained unsatisfactory. We had...
7.
Hotta K, Kiura K, Tabata M, Takigawa N, Tanimoto M, Ueoka H
Chest
. 2014 Dec;
146(6):e222-e225.
PMID: 25451370
No abstract available.
8.
Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, et al.
Eur J Cancer
. 2014 Aug;
50(16):2783-90.
PMID: 25172295
Background: Although thoracic irradiation (TRT) is a standard treatment for elderly patients with locally advanced non-small-cell lung cancer (LA-NSCLC), treatment outcomes are poor. We previously reported a phase I trial...
9.
Oishi K, Mimura-Kimura Y, Miyasho T, Aoe K, Ogata Y, Katayama H, et al.
Cytokine
. 2012 Oct;
61(1):84-9.
PMID: 23021430
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is characterized by severe worsening dyspnea of unknown etiology and high mortality without effective treatment. Recently, direct hemoperfusion with polymyxin B (PMX)-immobilized fiber...
10.
Okada T, Takigawa N, Kishino D, Katayama H, Kuyama S, Sato K, et al.
Acta Med Okayama
. 2012 Jun;
66(3):245-51.
PMID: 22729105
Cisplatin is used to treat lung cancer; however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of...